Insights

This paper highlights macro and micro factors affecting oncology and proposes a partnership-driven framework to catalyze innovation for oncology-focused biopharma – as well as the role that select high-impact technologies will have on the on the entire value-chain of cancer research and care delivery. 

Patient monitoring is an inherent part of patient management. Intermittent and continuous measurements have a range of uses, from defining disease states and characterising progression to informing therapeutic approaches and...

With a constant stream of good news about potential COVID-19 vaccines, we reflect on traditional viral vaccine manufacturing processes and how we apply what we’re learning during this pandemic to legacy techniques.

It was fantastic to win one of the coveted iF DESIGN AWARDS for Alma, our smart cooling case for injectable fertility drugs. International recognition was a nice boost to the team responsible for a concept with potential to improve quality of life for women facing the challenges of IVF treatment...

Our webinar reveals how device developers will need to maneuver through conservative, highly regulated, monopolistic yet fragmented healthcare systems that often provide contradictory incentives. Following the presentation, our audience had the opportunity to ask a variety of questions. Here’s what our experts had to say in reply.

Clinical trials are vital for informing pharmaceutical companies about drug action and efficacy, and for demonstrating the safety of new drugs. However, they can be notoriously expensive, time-consuming to conduct, and the commercial...

The recent launch of the Apple Watch Series 4 is the latest example of a device developed by a traditional consumer product company making a well-publicized entry into the patient-facing medical device market. Patient-facing devices...

Many of the dominant pharmaceutical companies operate partly, or wholly, in the generic drugs market. In 2016, the generics divisions of Teva, Mylan and Novartis all reported revenues in excess of $9bn with the top ten manufacturers...

The rising cost of clinical trials (CTs), coupled with the commercial risks of failure, mean it’s increasingly important to harness the power of real-world data to inform effective trial designs, better understand outcomes and maximise the likelihood of clinical success...

Elpenhaler® is ELPEN’s propriety classic DPI device, developed to administer various medications for the treatment of asthma and COPD (Figure 1). Each dose of medication is packed into the blister of an alu-alu strip..

Connected drug delivery products (Drug delivery devices with attached/incorporated capability that includes connectivity to wider digital services) continue to be a driving force in medical devices. In this whitepaper...

Low adherence to therapy is a recognized issue in respiratory disease and has driven the development of electronic sensors for monitoring inhaler use. To date, sensors for dry powder inhalers (DPIs) have...